METHODS AND COMPOSITIONS FOR CANCER THERAPY AND FOR PROGNOSTICATING RESPONSES TO CANCER THERAPY

摘要

A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24, N28 and N29 monoclonal antibodies are described which have been identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary cancers.